Thomas Seyfried, PhD, is a professor of biology at Boston College who specializes in the metabolic origins and treatment of cancer. He is the author of "Cancer as a Metabolic Disease" and co-developed the Glucose Ketone Index. His published research focuses on ketogenic metabolic therapy, mitochondrial metabolic theories of cancer, cellular fermentation mechanisms, and repurposed drug combinations for conditions such as glioblastoma.
The Glucose Ketone Index can be used as a clinical tool to monitor and manage all major chronic diseases and cancers.
"Our big paper that just came out last week, Frontiers in Science, talks about the glucose ketone index as a tool for managing all the major chronic diseases and cancers." (said at 0:08:56)
The Glucose Ketone Index (GKI) was introduced by Seyfried and colleagues as an experimental metric to track metabolic ketosis and blood glucose in preclinical models and preliminary trials of brain tumors (such as glioblastoma). Claiming that GKI is an established clinical tool to monitor and manage 'all major chronic diseases and cancers' is a substantial overstatement. Systematic reviews show that even in brain tumors, evidence for ketogenic metabolic therapy is limited, heterogeneous, and unproven for survival outcomes, and broad clinical utility across all chronic diseases has not been validated in clinical trials.
Ketogenic metabolic therapy combined with targeted drugs facilitates drug delivery across the blood-brain barrier for pediatric brain cancers.
"And I think that with the big paper that we had with Purna Mukherjee a couple of weeks ago in Cell Reports Medicine, we've shown how ketogenic metabolic therapy can facilitate drug delivery to manage these different cancers. Brain can—childhood brain cancer, number one killer of little kids. We know how to manage that now effectively without toxicity." (said at 0:10:28)
Evidence for ketogenic diet acting as a metabolic vehicle to enhance drug delivery and therapeutic efficacy for pediatric brain cancers comes entirely from preclinical animal models (juvenile syngeneic mice) and in vitro cell lines, rather than clinical human trials. A recent study in Cell Reports Medicine demonstrated that a ketogenic diet combined with repurposed/targeted drugs (mebendazole and devimistat) enhanced survival and reduced tumor invasion while allowing lower drug dosing in juvenile mouse glioblastoma models, but clinical efficacy in pediatric patients remains unproven.
- supports: Ketogenic diet as a metabolic vehicle enhancing the therapeutic efficacy of mebendazole an… (Cell reports. Medicine 2026)
"This study investigates the influence of nutritional ketosis on the therapeutic efficacy of mebendazole (MBZ) and devimistat (CPI-613) in invasive VM-M3 and non-invasive CT-2A glioblastoma models in juvenile syngeneic mice... The greatest reductions in tumor invasion and progression, together with prolonged survival, occurred when drug treatment was combined with a ketogenic diet (KD)... KD-enabled combination therapy allowed lower drug dosing, reduced toxicity, and improved survival, supporting further investigation of metabolically informed diet-drug strategies for pediatric gliomas." (abstract, results, passage verified)
pubmedfull study (doi)
Following the adoption of Western diets, 50% of Inuit populations suffer from cancer, dementia, and diabetes.
"I know that because I gave a lecture at Thunder Bay Medical School in Canada that serves the Inuit populations and they used to be some of the healthiest people on the planet and now they're some of the most unhealthy people. 50% have cancer and dementia and all kinds of diabetes. They never ate highly processed carbs and you give it to them now as wards of the state and the next thing you know they're all they have every kind of a chronic disease you can possibly imagine." (said at 1:09:55)
Epidemiological studies and systematic reviews demonstrate that dietary transition away from traditional diets toward Western, refined-carbohydrate diets has led to increased rates of non-communicable chronic diseases (including obesity, diabetes, and cardiovascular disease) among Inuit and other indigenous populations. However, the specific claim that 50% of Inuit populations suffer from cancer, dementia, and diabetes is a significant exaggeration. Cross-sectional epidemiological data from Canadian Arctic Inuit/Inuvialuit communities show that roughly 20% of adults report any chronic disease, with age-adjusted prevalence rates of approximately 9% for diabetes and 6% for cancer.
- contradicts: Prevalence and risk factors for self-reported chronic disease amongst Inuvialuit populatio… (Journal of human nutrition and dietetics : the official journal of the British Dietetic Association 2010)
"More than 20% of the 228 participants aged 19-84 years reported having a chronic disease. Age-adjusted prevalence was 28, 9, 9 and 6 per 100 for hypertension, heart disease, diabetes and cancer, respectively." (abstract, results, passage verified)
pubmedfull study (doi) - context: Dietary Transitions and Health Outcomes in Four Populations - Systematic Review. (Frontiers in nutrition 2022)
"Non-communicable chronic diseases (NCDs) such as obesity, type 2 diabetes, heart disease, and cancer were rare among non-western populations with traditional diets and lifestyles. As populations transitioned toward industrialized diets and lifestyles, NCDs developed." (abstract, background, passage verified)
pubmedfull study (doi)